

Table S1 The relationship between clinical characteristic and overall survival of TCGA cohort

	Amplification	Non-amplification	P value
N	199	109	
Age, years, mean (SD)	59.74 (11.88)	60.78 (14.22)	0.496
Gender (male), n (%)	150 (75.4)	63 (57.8)	0.002
Race, n (%)			<0.001
Asian	109 (54.8)	34 (31.2)	
Black or African American	9 (4.5)	5 (4.6)	
Not reported	6 (3.0)	2 (1.8)	
White	75 (37.7)	68 (62.4)	
AFP, ng/ml, mean (SD)	20,600.93 (166,204.61)	3,702.72 (26,575.26)	0.374
BMI, kg/m ² , mean (SD)	26.03 (9.95)	26.84 (6.43)	0.465
Inflammation, n (%)			0.005
Mild	58 (29.1)	24 (22.0)	
None	51 (25.6)	47 (43.1)	
Severe	15 (7.5)	2 (1.8)	
N/A	75 (37.7)	36 (33.0)	
Tumor grade, n (%)			<0.001
G1	20 (10.1)	30 (27.5)	
G2	91 (45.7)	52 (47.7)	
G3	76 (38.2)	25 (22.9)	
G4	11 (5.5)	0 (0.0)	
N/A	1 (0.5)	2 (1.8)	
Tumor stage, n (%)			0.122
Not reported	9 (4.5)	10 (9.2)	
Stage I	98 (49.2)	51 (46.8)	
Stage II	51 (25.6)	20 (18.3)	
Stage III	0 (0.0)	1 (0.9)	
Stage IIIA	35 (17.6)	18 (16.5)	
Stage IIIB	3 (1.5)	4 (3.7)	
Stage IIIC	3 (1.5)	5 (4.6)	
Residual tumor, n (%)			0.164
R0	180 (90.5)	95 (87.2)	
R1	9 (4.5)	2 (1.8)	
RX	7 (3.5)	9 (8.3)	
N/A	3 (1.5)	3 (2.8)	
Vascular tumor invasion, n (%)			0.854
Macro	7 (3.5)	5 (4.6)	
Micro	53 (26.6)	25 (22.9)	
None	108 (54.3)	63 (57.8)	
N/A	31 (15.6)	16 (14.7)	
TMB, Mut/Mb, mean (SD)	6.72 (6.31)	6.04 (5.82)	0.38

TCGA, The Cancer Genome Atlas; AFP, alpha-fetoprotein; BMI, body mass index; TMB, tumor mutation burden.